The state of Texas currently has 45 active clinical trials seeking participants for Type 2 Diabetes research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Innovative Automated Insulin Delivery System for Type 2 Diabetes
NCT06853990
Recruiting
The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Texas Diabetes & Endocrinology, P.A., Austin, Texas
Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
Register for Updates
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Juno Research, Houston, Texas +4 locations
Conditions: Type 2 Diabetes
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Velocity Clinical Research Abilene, Abilene, Texas +10 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Velocity Clinical Res-Dallas, Dallas, Texas +11 locations
Conditions: Type 2 Diabetes (T2D)
Register for Updates
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/29/2025
Locations: Hendrick Health, Abilene, Texas +8 locations
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Register for Updates
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/28/2025
Locations: Elligo Clinical Research Center, Austin, Texas +8 locations
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Register for Updates
Healthy Communities Through CHW Initiatives
NCT05965869
Recruiting
Latino(a)s suffer from poor social determinants of health (SODH) conditions more than non-minority populations, and being a minority is risk factor alone for diabetes. In the proposed study, investigators will assist church members in becoming Community Health Workers (CHWs), train them in diabetes, and to track the ability to address healthcare access and quality barriers using an online platform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Texas Medical Branch at Galveston, Galveston, Texas
Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus Risk
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792
Recruiting
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas +3 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Radiance Clinical Research, Lampasas, Texas +1 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/25/2025
Locations: Texas Childrens Hospital, Houston, Texas
Conditions: Type 2 Diabetes
Register for Updates
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas +5 locations
Conditions: Type 2 Diabetes
Register for Updates
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
Recruiting
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/23/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas +1 locations
Conditions: Healthy, Overweight, Obesity, Type 2 Diabetes
Register for Updates